📰 Nasdaq Nbse News
Nasdaq Nbse News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Nbse. Real-time updates on events, politics, business and more.
February 11, 2024
NeuBase Therapeutics (NASDAQ:NBSE – Get Free Report) and Gemini Therapeutics (NASDAQ:GMTX – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability. Earnings and Valuation This table compares NeuBase Therapeutics […]
February 3, 2024
NeuBase Therapeutics, Inc. (NASDAQ:NBSE – Get Free Report) shares dropped 3.3% on Thursday . The stock traded as low as $0.68 and last traded at $0.69. Approximately 37,086 shares changed hands during trading, a decline of 50% from the average daily volume of 74,431 shares. The stock had previously closed at $0.71. NeuBase Therapeutics Price […]
February 3, 2024
NeuBase Therapeutics, Inc. (NASDAQ:NBSE – Get Free Report) shares traded down 3.3% during trading on Thursday . The stock traded as low as $0.68 and last traded at $0.69. 37,086 shares were traded during mid-day trading, a decline of 50% from the average session volume of 74,431 shares. The stock had previously closed at $0.71. […]
November 28, 2023
NeuBase Therapeutics (NASDAQ:NBSE – Get Free Report) and Aditxt (NASDAQ:ADTX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk. Profitability This table compares NeuBase Therapeutics and Aditxt’s […]
November 12, 2023
NeuBase Therapeutics, Inc. (NASDAQ:NBSE – Get Free Report) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 8,900 shares, a decrease of 53.9% from the October 15th total of 19,300 shares. Based on an average trading volume of 2,280,000 shares, the days-to-cover ratio […]
September 11, 2023
NeuBase Therapeutics, Inc. (NASDAQ:NBSE – Get Free Report) major shareholder Corp Symetryx sold 74,852 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $1.80, for a total transaction of $134,733.60. Following the transaction, the insider now owns 605,149 shares in the company, valued […]
August 23, 2023
NeuBase Therapeutics, Inc. (NASDAQ:NBSE – Free Report) – Equities researchers at Chardan Capital increased their FY2023 earnings per share estimates for shares of NeuBase Therapeutics in a research note issued to investors on Wednesday, August 16th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings per share of ($5.19) for the […]
July 16, 2023
NeuBase Therapeutics, Inc. (NASDAQ:NBSE – Get Free Report) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 71,500 shares, a growth of 108.5% from the June 15th total of 34,300 shares. Based on an average trading volume of 72,200 shares, […]
July 1, 2023
NeuBase Therapeutics, Inc. (NASDAQ:NBSE – Free Report) saw a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 34,300 shares, a drop of 93.8% from the May 31st total of 554,800 shares. Based on an average trading volume of 62,600 shares, the short-interest ratio is […]
May 14, 2023
CM Management LLC lessened its holdings in NeuBase Therapeutics, Inc. (NASDAQ:NBSE – Get Rating) by 22.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 350,000 shares of the company’s stock after selling 100,000 shares during the period. CM Management LLC owned approximately 1.06% […]